Format

Send to

Choose Destination
Future Oncol. 2017 Jan;13(2):185-194. Epub 2016 Sep 7.

Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.

Author information

1
The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
2
Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, UK.
3
The Institute of Cancer Research, Cotswold Road, Sutton, SM2 5NG, UK.

Abstract

Primary and secondary resistance to currently available licensed tyrosine kinase inhibitors poses a real clinical challenge in the management of advanced gastrointestinal stromal tumors. Within the frame of early phase clinical trials novel systemic treatments are currently being evaluated to target both the well explored and novel emerging downstream effectors of KIT and PDGFRA signaling. Alternative therapeutic approaches also include exploring novel inhibitors of the KIT/PDGFRA receptors, immune checkpoint and cyclin-dependent kinase inhibitors. The final clinical trial outcome data for these agents are highly anticipated. Integration of new diagnostic techniques into routine clinical practice can potentially guide tailored delivery of agents in the treatment of a highly polyclonal, heterogeneous disease such as heavily pretreated advanced gastrointestinal stromal tumor.

KEYWORDS:

GIST; KIT; PFGFRA; novel therapy

PMID:
27600625
DOI:
10.2217/fon-2016-0194
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center